Skip to main content

Table 2 Patient interviews: Clinician-reported patient health informationa

From: Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings

  Total (N = 15) n (%)b
Menopausal status
 Pre-menopausal 3 (20.0%)
Not on gonadotropin-releasing hormone (GnRH) agonist treatment 3 (100.0%) c
 Post-menopausal 12 (80.0%)
Mammalian target of rapamycin (mTOR) inhibitor treatment
 Yes 3 (20.0%)
 No 12 (80.0%)
Recurrent or progressive disease refractory to non-steroidal aromatase inhibitor (NSAI), tamoxifen, or fulvestrant
 Yes 6 (40.0%)
 No 9 (60.0%)
Eastern Cooperative Oncology Group score
 0 1 (6.7%)
 1 11 (73.3%)
 2 3 (20.0%)
Cyclin-dependent kinase (CDK4/6) inhibitor treatment
 Yes 5 (33.3%)
 No 10 (66.7%)
Metastatic sited
 Bone 13 (86.7%)
 Lung 2 (13.3%)
 Liver 3 (20.0%)
 Lymph node 1 (6.7%)
 Skin 1 (6.7%)
  1. aInformation reported by clinician on the Subject Clinical Screener
  2. bUnless other statistic indicated
  3. cThis characteristic was only reported by the clinician for subjects who were pre-menopausal at diagnosis. The clinician for one subject reported menopausal status at the time of the study (post-menopausal); however, it was determined that treatment caused the subject to begin menopause. Thus, the subject is characterized as pre-menopausal. Data for this subject regarding treatment with a GnRH agonist were not provided
  4. dResponses are not mutually exclusive